{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-116903","form_type":"8-K","ticker":"BGMS","cik":"0001130166","company_name":"Bio Green Med Solution, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.742592+00:00","generated_at":"2026-05-30T01:33:53.802587+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Cyclacel Q3 net loss $2.0M, cash $3.0M; Nasdaq extension to Dec 24; going concern doubt","bullets":["Net loss $2.0M for Q3 2024 vs $6.0M a year ago; cash $3.0M as of Sept 30, 2024.","R&D expenses fell to $1.0M from $5.2M; fadraciclib R&D $0.9M vs $3.6M.","Nasdaq granted extension to Dec 24, 2024 to regain minimum stockholders' equity compliance.","Substantial doubt about going concern; may curtail operations or file for bankruptcy if funding not secured.","Initial safety/efficacy data from 12 patients in fadraciclib Phase 2 cohort presented at Triple Meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-116903","json":"https://secwatch.observer/filing/0001104659-24-116903.json","markdown":"https://secwatch.observer/filing/0001104659-24-116903.md","text":"https://secwatch.observer/filing/0001104659-24-116903.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130166/000110465924116903/0001104659-24-116903-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130166/000110465924116903/tm2428051d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:33:53.802587+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}